By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genmab A/S 

Toldbodgade 33

Copenhagen    K-1253  Denmark
Phone: 45-7020-2728 Fax: 45-7020-2729


Key Statistics

Ownership: Public

Web Site: Genmab A/S
Symbol: GEN.CO



Bionomics Limited  Anti-angiogenesis therapeutic antibody development

Company News
Genmab A/S (GEN.CO) Announces FDA Approval Of DARZALEX (Daratumumab) For Multiple Myeloma And Updates Financial Guidance 11/17/2015 7:57:43 AM
Genmab A/S (GEN.CO) Release: Major Shareholder Announcement 9/30/2015 8:00:11 AM
Genmab A/S (GEN.CO) Release: Data Published In The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses In Heavily Pre-Treated Relapsed Or Refractory Multiple Myeloma Patients 8/27/2015 7:16:19 AM
Genmab A/S (GEN.CO) Announces Completion Of Rolling Submission Of Biologics License Application For Daratumumab In Multiple Myeloma And Achievement Of A USD 15 Million Milestone 7/10/2015 6:54:39 AM
Genmab A/S (GEN.CO) Announces European Regulatory Submission For Ofatumumab As Maintenance Therapy For Relapsed CLL 7/7/2015 7:01:29 AM
Genmab A/S (GEN.CO) Announces Start Of Rolling Submission Of Biologics License Application For Daratumumab For Double Refractory Multiple Myeloma To The FDA 6/8/2015 7:26:46 AM
Genmab A/S (GEN.CO) Gains License To Antibody Panel Targeting CD19 6/2/2015 7:22:33 AM
Genmab A/S (GEN.CO) Release: Ofatumumab And Daratumumab Data To Be Presented At 20th Congress Of European Hematology Association 5/21/2015 2:14:24 PM
BioNTech, Genmab A/S (GEN.CO) Forge $15 Million Immuno-Oncology Pact 5/19/2015 6:02:27 AM
Genmab A/S (GEN.CO) Achieves USD 10 Million Milestone In Daratumumab Collaboration With Janssen Biotech Inc. (JNJ) 4/17/2015 8:00:32 AM